Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy

Amanda Lusa1*, Carolina Alvarez2, Shruti Saxena Beem2, Todd A. Schwartz3 and Rumey Ishizawar1

Abstract

Introduction: Immune checkpoint inhibitors (ICIs) enhance the immune system's ability to target and destroy cancer cells, but this non-specific immune overactivation can result in immune-related adverse events (irAEs). Patients with underlying autoimmune diseases were excluded from the original ICI clinical trials because of the theoretical risk of irAEs. This study aimed to evaluate the risk of irAEs in patients with pre-existing rheumatologic diseases on ICIs, impact of anti-rheumatic therapy on irAEs, and malignancy outcomes.

Methods: We performed a retrospective chart review of patients with a pre-existing rheumatologic diagnosis receiving ICIs at the University of North Carolina from 2014 to 2019. Risk differences (RD) and asymptotic 95% confidence intervals (95% CIs) using a continuity correction along with odds ratios (OR) and exact 95% CIs were produced between pre-specified risk factors and flares of the underlying rheumatologic disease and/or irAEs. Kaplan–Meier survival estimates for time to unfavorable cancer response between subsets of patients were compared using the log-rank test.

Results: We identified 45 patients receiving an ICI with an underlying rheumatologic diagnosis, including 22 with rheumatoid arthritis (RA). Overall, 13 patients (29%) had a flare of their autoimmune disease, 20 patients (44%) had a new-onset irAE, and 27 (60%) had either a flare or new-onset irAE. Patients with RA had higher risk of flares compared to those with other rheumatologic disorders (45% vs 13%, RD 32%, 95% CI 2.0–56.8); all RA flares were ≤ grade 2 and treated in the outpatient setting. Concurrent treatment of the rheumatologic disease at the start of ICI therapy was not associated with a reduced risk of flare (OR 0.86, 95% CI 0.19–3.76) or new onset irAE (OR 3.21, 95% CI 0.83–13.6) compared to those not on anti-rheumatic medications. Anti-rheumatic therapy did not impact time to unfavorable malignancy outcome (p = 0.52).

Conclusion: The majority of our study cohort experienced a flare or new onset irAE with ICI treatment. Treatment with anti-rheumatic therapy did not prevent disease flares or new onset irAEs, but did not negatively impact malignancy outcomes. Research is needed to determine safe anti-rheumatic therapy options to prevent flares and irAEs that do not interfere with malignancy outcomes.

*Correspondence: amanda_lusa@med.unc.edu

1 Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, USA

Full list of author information is available at the end of the article
Keywords: Immune-related adverse event, Immune checkpoint inhibitor, Rheumatologic disease, Anti-rheumatic therapy, Rheumatoid arthritis, Disease flare

Background
Immune related adverse events (irAEs) are unintended, although mechanistically predictable, consequences of immune checkpoint inhibitor (ICI) therapy [1]. The first approved ICI therapy was ipilimumab, a cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist, in 2011 for melanoma. Since then, this field has rapidly expanded with six additional ICIs targeting PD-1/PD-L1 pathways approved for treating a wide variety of malignancies both as first line and second line therapies [2]. Due to the immune modulation effects of ICIs and risk for irAEs, patients with underlying autoimmune diseases were excluded from the initial studies of ICI therapy. Presentations of irAEs can appear similar to rheumatologic disorders such as inflammatory arthritis [3], polymyalgia rheumatica, sicca symptoms [4], and myositis [5], suggesting that ICIs may increase the risk of disease flares in individuals with pre-existing rheumatologic disease. The prevalence of rheumatoid arthritis (RA) in the general population worldwide is about 0.5% [6]. Per the National Institute of Health Autoimmune Diseases Coordinating Committee Report from October 2000, the collective prevalence of all autoimmune conditions affects at least 5% of the United States population. Patients with rheumatologic autoimmune conditions also have a higher risk for malignancies compared to general population due to inherent altered immune systems as well as risks posed from immunosuppressive therapy to treat [7]. As ICI therapy can prolong survival in the setting of otherwise fatal malignancies, it is crucial to determine the true risks for irAEs and cancer outcomes in patients with underlying autoimmune disease who are indicated to receive ICI.

To date there have been several published case series and cohort studies looking at the incidence of irAEs and disease flares in patients with pre-existing autoimmune diseases, including those with rheumatologic conditions [8–15]. Several groups have shown flares in a majority of patients with RA [8, 11, 16, 17]. However, data regarding effects of immunosuppression on irAE and flare risk, as well as cancer treatment outcomes, is minimal and based on cohorts that include non-rheumatologic patients as well [9, 11, 14].

This study aimed to evaluate the risk of flares and irAEs in patients with underlying autoimmune rheumatologic disease treated with ICIs at the University of North Carolina (UNC) and to investigate the impact of anti-rheumatic therapy on the incidence of immune events and malignancy outcomes.

Methods
Patient selection
This study was conducted through retrospective chart review of patients with autoimmune rheumatologic diseases treated with ICIs at UNC from 2014 to 2019. This study was reviewed and approved by the Institutional Review Board of the University of North Carolina at Chapel Hill prior to start of data collection under IRB 17-1841. Due to the retrospective design and observational nature of the study, the requirement for informed consent was waived by the ethics committee of the University of North Carolina at Chapel Hill. Patients treated with ICIs at UNC were initially identified through i2B2 (Informatics for Integrating Biology and the Bedside) and the Carolina Data Warehouse for Health (CDW-H). The i2b2 is the flagship tool developed by the i2b2 Center, an NIH funded National Center for Biomedical Computing based at Partners HealthCare System, and CDW-H is a central data repository containing clinical, research, and administrative data sourced from the UNC Health Care System, with the ability to query most data elements as far back as mid-2004. The i2b2 linked with the CDW-H to query deidentified aggregate data to identify our cohort of patients on ICIs. Due to a transition in electronic medical records systems being used at UNC in 2014, clinical data from the legacy system was not included in this analysis despite FDA approvals for ICIs being available since 2011. Among 2842 patients treated with ICIs at UNC through December 31st, 2019, those with underlying rheumatologic diseases were identified using EMERSE (Electronic Medical Record Search Engine). EMERSE allows users to search free text (unstructured) clinical notes from the electronic health record [18]. In the EMERSE search we used these specific terms: “rheumatoid arthritis”, “psoriatic arthritis”, “ankylosing spondylitis”, “polymyalgia rheumatica”, “sarcoidosis”, “lupus”, “sjogren’s”, “connective tissue disease”, “scleroderma”, “vasculitis”, “angiitis”, and “myositis”. Chart review was performed in the electronic medical record. In total 45 patients were identified that carried a chart diagnosis listed above and had either been on or discussed treatment with a physician that supported their autoimmune diagnosis. There were an additional 34 patients with a chart diagnosis for rheumatic disease not supported by available records or
a treatment plan who were excluded due to concern for misclassification.

In addition to rheumatologic diagnosis, we also extracted data on demographics (sex, age at malignancy diagnosis), ICI drug including anti-cytotoxic T-lymphocyte associated protein 4 (anti-CTLA4) therapy (ipilimumab), programmed cell death protein 1 (PD-1) inhibitors (pembrolizumab, nivolumab), or programmed death ligand 1 (PD-L1) inhibitors (atezolizumab, durvalumab), co-morbidities of interest (other autoimmune disease, prior malignancy, hypothyroidism, cardiovascular disease), anti-rheumatic therapy at the time ICI was started (hydroxychloroquine, disease modifying anti-rheumatic drugs (DMARDS), biologics, JAK inhibitors, corticosteroids, combination therapies), and autoimmune disease control before ICI therapy was started as documented by the oncologist. At the time of this study, the most recently approved ICIS - avelumab (2017) and cemiplimab (2018) - were not available to query in the i2b2 database and were excluded from analysis. Eastern cooperative oncology group (ECOG) score was also recorded but only available for 30 patients and was therefore not used in analysis because of the limited data set.

Outcomes
Study outcomes of interest were occurrences of rheumatologic disease flares and new onset irAEs, and cancer outcomes as assessed by chart review.

Flares were defined by clinical documentation of an exacerbation of a patient’s underlying rheumatologic disease, and irAEs were defined by clinical documentation of a new-onset inflammatory responses separate from the patient’s underlying disease. All irAEs were categorized by common terminology criteria for adverse events (CTCAE) grade, either by the oncology care team or denovo by the study team if oncology notes did not specify. The specific irAEs were further classified by organ system. The time from the first dose of ICI to the onset of the flare or irAE was calculated. Information on treatment for the flare or irAE was collected, including the use of systemic corticosteroids, as was information on whether the ICI was held.

Cancer outcomes were ascertained though chart review of oncology notes and were noted as complete remission, partial remission, stable disease, mixed response, progression, or death as documented by the oncology team using RECIST criteria. During analysis, cancer outcomes were categorized as favorable (partial remission or stable disease) or unfavorable (mixed response, progression, or death). Subjects with a favorable cancer response (i.e., partial remission or no progression) were censored on the date of their last documented cancer response assessment after the start of ICI therapy. Subjects with an unfavorable cancer response (i.e., mixed, progression on therapy, progression off therapy, or death) were defined as having the event of interest, with the number of days determined from start of ICI therapy.

Statistics
Descriptive statistics were used to summarize study patients and relevant variables. Counts and percentages were produced for categorical variables, while means and standard deviations (SD) were computed for continuous variables.

Odds ratios (OR) and exact 95% confidence intervals (95% CI) were produced between pre-specified risk factors and flares or irAEs. In addition, risk differences (RD), characterized as differences in percentages, and their corresponding asymptotic 95% CI using a continuity correction, were produced for certain risk factors (age, sex, rheumatologic disease type, anti-rheumatic treatment at the time of ICI therapy, and rheumatologic disease control) to aid in interpretation.

Kaplan–Meier estimates for time to unfavorable cancer response were produced and separately stratified for (1) incidence of a flare or irAE versus those without; (2) occurrence of a flare or irAE that required oral or intravenous steroids versus those without an event requiring systemic steroids; (3) ICI being held due to a flare or irAE versus continuing ICIs; (4) treatment for the rheumatologic disease during ICI treatment versus no rheumatologic treatment; (5) rheumatoid arthritis versus other rheumatologic disease. Kaplan–Meier estimates were produced by stratum and the log-rank test was used to assess for differences in time to unfavorable cancer response between levels of the strata described above.

All analyses were performed with SAS version 9.4 (SAS institute Inc., Cary, NC). Statistical significance was determined at an alpha level of 0.05.

Results
We identified 45 patients with pre-existing autoimmune rheumatologic disease on ICI therapy, including 22 with rheumatoid arthritis, 5 with systemic lupus erythematosus, 4 with polyarthritis rheumatic, 4 with psoriatic arthritis, and 10 with other conditions (Table 1). The mean (±SD) age was 68 (±11.2) years. The majority of patients were white (n = 34, 76%) and female (n = 31, 69%). The most common indication for ICI was non-small cell lung cancer (NSCLC, n = 22, 49%). Most patients were treated with PD-1 inhibitors (n = 37, 82%).

The incidence of flare of the underlying rheumatologic disease was 29% (n = 13) and the incidence of new onset irAEs was 44% (n = 20), with a total of 60% (n = 27) of the patients experiencing either a flare or irAE (Table 2). Of the new onset irAEs, gastrointestinal
events were most common \( (n = 7, 16\%) \), followed by pulmonary events \( (n = 5, 11\%) \). There were 3 new-onset rheumatologic irAE events in patients without those features as a part of their pre-existing disease. These included arthralgias in a patient with cutaneous discoid lupus, extensor tenosynovitis in a patient with polymyalgia rheumatica, and bone pain in a patient with Sjogren’s syndrome. Nine patients had multiple events, which could include a flare of their underlying rheumatic condition and/or new onset irAE events.

In terms of severity, 8 patients experienced a grade 3 or higher new onset irAE based on CTCAE criteria. One of the patients passed away from fulminant pneumonitis. All flares of the underlying disease were grade 2 or lower. The median (interquartile range) time to

Table 1
Baseline patient characteristics

| Patient characteristic               | \( n^* \) | %* |
|--------------------------------------|----------|----|
| Age, mean ± SD                       | 67.9 ± 11.2 |
| Gender, female                       | 31       | 68.9 |
| Race                                 |          |    |
| White                                | 34       | 75.5 |
| Black or African American            | 8        | 17.8 |
| Other \(^1\)                         | 3        | 6.7 |
| Rheumatologic disease                |          |    |
| Rheumatoid arthritis                 | 22       | 48.9 |
| Lupus                                | 5        | 11.1 |
| Polymyalgia rheumatica               | 4        | 8.9 |
| Psoriatic arthritis                  | 4        | 8.9 |
| Other \(^2\)                         | 10       | 22.2 |
| Malignancy type                      |          |    |
| Non-small cell lung cancer           | 22       | 48.9 |
| Renal cell carcinoma                 | 5        | 11.1 |
| Melanoma                             | 4        | 8.9 |
| Other \(^3\)                         | 14       | 31  |
| Comorbidities                        |          |    |
| Other autoimmune disease \(^4\)     | 4        | 8.9 |
| Prior malignancy                     | 10       | 22.2 |
| Hypothyroidism                       | 16       | 35.6 |
| Cardiovascular disease               | 13       | 28.9 |
| Immune checkpoint inhibitor          |          |    |
| Pembrolizumab                        | 21       | 46.7 |
| Nivolumab                            | 16       | 35.6 |
| Atezolizumab                         | 5        | 11.1 |
| Durvalumab                           | 1        | 2.2 |
| Ipilimumab                           | 1        | 2.2 |
| Nivolumab+pembrolizumab              | 1        | 2.2 |
| Anti-rheumatic therapy at initiation of ICI | 22 | 48.9 |
| Hydroxychloroquine                   | 11       | 24.4 |
| DMARD \(^5\)                         | 4        | 8.9 |
| JAK inhibitor \(^6\)                 | 1        | 2.2 |
| Oral corticosteroid                  | 3        | 4.4 |
| Combination \(^7\)                   | 3        | 8.9 |
| Autoimmune disease controlled before ICI therapy | 40 | 88.9 |
| Yes                                  | 5        | 11.1 |
| Treatment line                       |          |    |
| 1                                    | 19       | 42.2 |
| 2                                    | 17       | 37.8 |
| 3 or more                            | 9        | 20.0 |

\(^1\) ICI, immune checkpoint inhibitor; \(^2\) DMARD, disease modifying anti-rheumatic drug; \(^3\) JAK, Janus kinase

\(^*\) Unless otherwise specified

\(^1\) Other races include Asian \((n = 1)\) and unknown \((n = 2)\)

\(^2\) Other rheumatologic disease include anklyosing spondylitis \((n = 2)\), dermatomyositis \((n = 1)\), limited scleroderma \((n = 2)\), sarcoidosis \((n = 2)\), Sjogren’s syndrome \((n = 2)\), and undifferentiated connective tissue disease \((n = 1)\)

\(^3\) Other malignancy types include bladder cancer \((n = 1)\), breast cancer \((n = 3)\), endometrial carcinoma \((n = 2)\), merkel cell carcinoma \((n = 1)\), small cell lung cancer \((n = 3)\), squamous cell carcinoma of the skin \((n = 1)\), squamous cell of the tongue \((n = 1)\), poorly differentiated lung cancer \((n = 2)\)

\(^4\) Other autoimmune diseases include autoimmune hepatitis \((n = 1)\), Grave’s disease \((n = 2)\), and psoriasis \((n = 1)\)

\(^5\) DMARDS include methotrexate \((n = 2)\), sulfasalazine \((n = 1)\), leflunomide \((n = 1)\)

\(^6\) JAK inhibitor includes tofacitinib \((n = 1)\)

\(^7\) Combinations include methotrexate and etanercept, hydroxychloroquine and prednisone, and tacrolimus and prednisone (for heart transplant)

Table 2
Immune event outcomes

| Outcome                                                                 | \( n^* \) | %* |
|-------------------------------------------------------------------------|----------|----|
| Flare \(^1\)                                                            | 13       | 28.9 |
| irAE \(^2\)                                                             | 20       | 44.4 |
| Gastrointestinal                                                        | 7        | 15.5 |
| Pulmonary                                                               | 5        | 11.1 |
| Dermatologic                                                            | 4        | 8.9 |
| Endocrine                                                               | 3        | 6.7 |
| Rheumatologic                                                           | 3        | 6.7 |
| Other                                                                   | 2        | 4.4 |
| Any event (flare or irAE)                                               | 27       | 60.0 |
| Multiple events                                                         | 9        | 20.0 |
| Severe events (grade 3 +)                                               | 8        | 17.8 |
| Death (grade 5 event)                                                   | 1        | 2.2 |
| Flare/irAE requiring systemic steroids                                   | 21       | 46.7 |
| Unfavorable cancer response (M/PG/D)                                    | 37       | 82.2 |
| Median time to unfavorable cancer response, median (95% CI) days        | 139      | (98, 193) |

irAE, immune related adverse event; M, mixed response; PG, progressive disease; D, death

\(^*\)Unless otherwise specified

\(^1\) Flare of the underlying rheumatologic disease as defined by clinical documentation of an exacerbation of a patient’s underlying rheumatologic disease

\(^2\) New-onset immune related adverse event distinct from pre-existing disease
flare was 28 days (21–63), and to an irAE was 32 days (20–56). The majority of patients were treated with systemic oral or intravenous steroids for their flare or irAE (n = 21), while the minority did not require systemic steroids (n = 6) (Table 3). Regarding other immunosuppressive treatments for flares or irAEs, one patient with a grade 2 rheumatoid arthritis flare resumed hydroxychloroquine in addition to starting an oral corticosteroid, and one patient with grade 3 colitis required infliximab followed by vedolizumab in addition to corticosteroids. With the exception of the patient who passed from grade 5 fulminant pneumonitis, all patients with grade 3 or higher events saw a resolution in flare and/or irAE in response to holding ICI therapy and systemic steroids.

We assessed whether ICI therapy was held at time of a flare of irAE. In total 16 of the patients who had an immune event required their ICI to be held (Table 3). ICI was held at the time of an immune event primarily for patients with grade 2 or higher events, though it was also held temporarily in one patient with grade 1 thyroiditis who required radiation, and permanently in another patient with grade 1 pneumonitis.

Associations between pre-specified risk factors and flares or new onset irAEs are shown in Table 4. The incidence of flares was higher in the RA population compared to those with other rheumatologic diseases (45% vs 13%, [OR 5.34, 95% CI 1.09–36.3], [RD 32%, 95% CI 2.0–56.8%], (Fig. 1)). However, the incidence of new onset irAEs was not higher in the RA group (41% vs 48%, [OR 0.76 95% CI 0.20–2.86], [RD 7%, 95% CI -23–36%]). Age and sex were not associated with the risk of flares or irAEs.

Out of the 45 patients with pre-existing rheumatologic disease, 22 of these patients were on established anti-rheumatic treatment at the time ICI therapy was initiated. The most common anti-rheumatic treatment was hydroxychloroquine (n = 11, 24%) followed by DMARDs (n = 4, 9%), detailed in Table 1. There were no statistically significant effects seen in the odds of flares (OR 0.86, 95% CI 0.19–3.76) or new onset irAEs (OR 3.21, 95% CI 0.83–13.6) between those on versus off anti-rheumatic therapy (Table 4). Additionally, there were no associations between autoimmune disease control status before ICI therapy and risk of flares or irAEs (Table 4).

In Table 5, the frequencies of flares and irAEs, including severities and management, are further delineated by underlying rheumatic disease type. For each rheumatic disease type affected by flare or irAE, the majority had ICI therapy held or required systemic steroids. The majority of adverse events were of Grade 1 or 2, rather than of higher severity i.e., Grade 3 or higher (Tables 2 and 5). There was only 1 death clearly linked to an immune related adverse event (Table 2).

Table 3: Flare and irAE event management among those with a flare or irAE

| Required systemic steroids | n | % |
|----------------------------|---|---|
| Yes | 21 | 77.8 |
| No | 6 | 22.2 |
| ICI therapy held | | |
| Yes | 16 | 59 |
| No | 11 | 41 |

Table 4: Bivariate analysis of risk factors for flares and irAEs

| Rheumatologic disease | No flares n (%) | Flares n (%) | OR (exact 95% CI) | No irAEs n (%) | irAEs n (%) | OR (exact 95% CI) |
|-----------------------|-----------------|-------------|-----------------|---------------|-------------|-----------------|
| Other (n = 23) | 20 (87) | 3 (13) | Reference | 12 (52) | 11 (48) | Reference |
| RA (n = 22) | 12 (55) | 10 (45) | 5.34 (1.09–36.3) | 13 (59) | 9 (41) | 0.76 (0.20–2.86) |
| Age | | | | | | |
| < 65 (n = 17) | 12 (71) | 5 (29) | Reference | 12 (71) | 5 (29) | Reference |
| ≥ 65 (n = 28) | 20 (71) | 8 (29) | 0.96 (0.21–4.65) | 13 (46) | 15 (54) | 2.71 (0.66–12.6) |
| Gender | | | | | | |
| Female (n = 31) | 21 (68) | 10 (32) | Reference | 16 (52) | 15 (48) | Reference |
| Male (n = 14) | 11 (79) | 3 (21) | 0.58 (0.08–2.93) | 9 (64) | 5 (36) | 0.60 (0.13–2.56) |
| Rheumatologic treatment | | | | | | |
| No (n = 23) | 16 (70) | 7 (30) | Reference | 16 (70) | 7 (30) | Reference |
| Yes (n = 22) | 16 (73) | 6 (27) | 0.86 (0.19–3.76) | 9 (41) | 13 (59) | 3.21 (0.83–13.6) |
| Autoimmune disease control before ICI therapy | | | | | | |
| No (n = 5) | 4 (80) | 1 (20) | Reference | 1 (20) | 4 (80) | Reference |
| Yes (n = 40) | 28 (70) | 12 (30) | 1.70 (0.15–91.4) | 24 (60) | 16 (40) | 0.17 (0.00–1.96) |
Overall, 82% (n = 37) of patients in this cohort had an unfavorable cancer outcome (mixed response, progression, death) and there were no complete responders (Fig. 2). Of the 8 patients who did not progress, 4 had lung adenocarcinomas, 1 had small cell lung cancer, 1 had poorly differentiated lung cancer, 1 had breast cancer, and 1 had renal cell carcinoma. Kaplan–Meier curves for time to unfavorable cancer outcome separately by occurrence of a flare or irAE, whether ICI therapy was continued or held after an immune event, administration of systemic steroids for treatment of an immune event, use of anti-rheumatic therapy during ICI treatment, and those with RA versus other rheumatologic diagnoses, are shown in Figs. 3a–e. There were no statistically significant differences in time to an unfavorable cancer outcome between levels of any of these stratification variables. We did not analyze for mortality differences due to the small cohort size and that some patients were lost to follow-up without a reported mortality outcome.

**Discussion**

We present an analysis of 45 patients with underlying autoimmune rheumatologic diseases who were treated with ICIs from 2014 to 2019 at UNC. The majority of patients experienced either a disease flare or new onset irAE, which is similar to findings in other cohorts with a variety of autoimmune diseases [12]. The incidence specifically of new-onset irAEs in our cohort (44%) was higher than that seen in a meta-analysis looking at 2392 patients from 23 clinical trials where the incidence of irAEs was 26% in those on anti-PD1 therapy and 14% in those on PD-L1 therapy [19]. In contrast, the incidence of irAEs was higher in those on anti-CTLA-4 therapy in the meta-analysis (54%), but our study only had one patient on this class of medications, so no firm conclusions can be drawn. Raw data were also collected on the 6 patients who received concurrent chemotherapy with ICI treatment. However, the number of patients in this study was too small to meaningfully complete sub-analyses based on concurrent therapy and malignancy type. This would be an area of future direction using a larger cohort with a broader cancer therapeutic regimen including more anti-CTLA-4 and/or concurrent chemotherapy.

Similar to other groups [8, 11, 14, 16, 17], we found a relatively high incidence of underlying disease flares, but not irAEs, in the RA population compared to those with other autoimmune diseases. The incidence of RA flares in these cohorts has ranged from 40 to 75%, showing it is a significant risk that should be addressed with the patient in pre-immunotherapy discussions. Fortunately, RA patients with flares are typically able to continue ICI therapy. For instance, in a prior RA cohort of 22 patients
| Feature                        | RA (n = 22) | Lupus (n = 5) | PMR (n = 4) | PsA (n = 4) | AS (n = 2) | Limited SSc (n = 2) | Sarcoidosis (n = 2) | SS (n = 2) | DM (n = 1) | UCTD (n = 1) |
|-------------------------------|-------------|---------------|-------------|-------------|------------|-------------------|-------------------|------------|------------|-------------|
| Flare (n = 13)               | 10          | 0             | 0           | 1           | 1          | 0                 | 0                 | 1          | 0          | 0           |
| irAE (n = 20)                | 9           | 3             | 2           | 1           | 2          | 0                 | 1                 | 1          | 0          | 1           |
| AEs (Grade 1–2) (n = 19)     | 11          | 3             | 1           | 0           | 2          | 0                 | 0                 | 2          | 0          | 0           |
| SAEs (Grade 3+) (n = 8)      | 4           | 0             | 1           | 1           | 0          | 0                 | 1                 | 0          | 0          | 1           |
| ICI therapy held (n = 16)    | 6           | 3             | 1           | 1           | 2          | 0                 | 1                 | 1          | 0          | 1           |
| Required systemic steroids (n = 21) | 12       | 1             | 2           | 1           | 2          | 0                 | 1                 | 1          | 0          | 1           |

RA, Rheumatoid arthritis; PMR, Polymyalgia Rheumatica; PsA, Psoriatic Arthritis; AS, Ankylosing Spondylitis; SSc, Scleroderma; SS, Sjogren’s Syndrome; DM, dermatomyositis; UCTD, undifferentiated connective tissue disease; irAE, immune related adverse event; AE, adverse event; SAE, serious adverse event; ICI, immune checkpoint inhibitor
with RA treated with ICIs, 55% had a flare of disease, but only two had to discontinue treatment due to the severity of the reaction [17]. In our cohort, of the 10 patients with an RA flare all events were grade 2 or lower, and only one required the ICI to be held permanently which was confounded by development of malignant pleural effusions and transition to hospice. Seven of the RA patients with a flare responded to prednisone therapy. The higher rate of RA flares in our cohort of patients treated primarily with PD-1 pathway inhibitors may speak to underlying mechanisms in RA pathogenesis. Prior animal studies have shown the development of inflammatory arthritis in PD-1 knockout mice and histopathologic studies showing increased expression of PD-1 and PD-L1 in synovial tissue from RA patients [20–22].

We did not find a statistically significant impact of anti-rheumatic therapy on the incidence of flares, new onset irAEs, or cancer outcomes. There was an interesting trend where the use of anti-rheumatic therapy, primarily hydroxychloroquine in our cohort, was associated with a higher risk of a novel irAE presentation and perhaps a lower risk of a rheumatologic disease flare. This discordance between disease flare and irAE presentations suggest that there may be different mechanisms leading
Fig. 3 (See legend on previous page.)
to these disease presentations. At the same time, it is unclear how to extrapolate from this finding given low patient numbers and lack of statistical significance. Since hydroxychloroquine is not known to interfere with T-cell mediated cytotoxicity directly, there is the possibility that these outcomes may have been different if patients were on more aggressive immunosuppression for their rheumatologic disease. While our study focused on examining the rheumatologic population, prior studies have looked at similar questions about the benefit of immunosuppression in patients on ICIs with diverse autoimmune diseases. Regarding incidence of flares, Menzies et al. [14] found a trend towards a higher rate of flares in those not taking concomitant anti-rheumatic therapy; in contrast Leonardi et al. found no association between flares and such therapy, in agreement with the present results. Previous data on the topic of cancer outcomes have been conflicting. Two groups have reported worse progression free survival [11] or response rates [14] in those on anti-rheumatic therapy during ICI treatment, while others have shown no impact of these medications on cancer outcomes [9], in line with our findings.

Malignancy outcomes in this cohort of patients treated with ICIs were poor overall, with only 18% having a favorable response including partial remission or no progression, and no patients having a complete response. This is likely due to the high percentage of patients treated for solid malignancies like NSCLC, where rates of complete remission have been as low as 1.5% [23]. This contrasts with metastatic melanoma where complete remission rates around 16% are reported [24]; our study only included four melanoma patients.

We also looked at cancer outcomes based on the use of systemic steroids for treatment of immune events. The majority of the data to date on the risk of poor cancer outcomes in those on steroids while on ICIs comes from populations without pre-existing rheumatologic disease. In a large meta-analysis, the use of concurrent steroids was associated with increased risk of cancer progression or death [25]. This may reflect the indication for steroid therapy rather than a true medication effect as others have only noted this risk in patients on palliative corticosteroids [26]. We found no association between systemic steroids and poor cancer outcomes suggesting possible confounders in earlier studies. However, we did not stratify by steroid dose, and there is the possibility of a dose effect at which one may see a negative impact. In addition, we did not assess for steroid use under other clinical indications beyond disease flare or irAEs and this may be an area to explore in the future regarding cancer outcome.

While others have shown that the occurrence of a flare or irAE is associated with a better malignancy outcome [3], our study did not show that association, possibly due to limited statistical power. Additionally, by including death due to any cause in our definition of poor malignancy outcomes, we included factors other than progression of disease since some deaths were likely related to infections, co-morbidities, or non-ICI treatment complications.

The limitations of our study, similar to other published cohorts, include limited sample size and lack of a comparator group without rheumatologic autoimmune disease. While the recent publication by van der Kooij et al. [12] included a larger population of patients with autoimmune rheumatologic disease, they focused on grade 3 or higher irAEs, while we included all grades of irAEs and distinguished between disease flare to look at the risks more precisely in this specific patient population. One strategy to potentially capture more patients would be to widen our search criteria to include disease abbreviations. Additionally, since UNC is a tertiary care center, some patients had an offsite rheumatologist which limited historical rheumatologic disease data. For inclusion into this study, all patients had a documented plan of care regarding management of their autoimmune disease detailed in the oncology notes. Due to the retrospective nature of this review and reliance on clinical documentation we were also unable to obtain baseline ECOG scores for all patients, which limited our ability to analyze this important variable that independently correlates with poor outcomes. Another limitation of this study was the lack of detailed documentation on duration and cumulative dose of steroids which prevented a more complete analysis of the effect of steroid use on cancer outcome.

The primary strength of our study is that we completed an in-depth chart review with descriptive analysis. Not only were we able to complete comprehensive mining through a central data repository and utilize search tools to identify cancer patients of interest, but through our descriptive analysis complete a careful review confirming cancer outcomes, rheumatologic flares, and irAE presentations. This is a unique patient population often not included in ICI cancer trials due to concerns for inciting disease flare or heightened risk for irAEs. Our study included a large RA cohort, which allowed for independent analysis on this group. This allowed us to show that RA patients while at higher risk for disease flare, had similar risk for irAEs to general population and no worse outcomes compared to those with other rheumatologic diseases (Fig. 3e).

These results support that patients with stable pre-existing rheumatologic diseases including rheumatoid arthritis should not be excluded from ICI therapy to treat malignancy. To optimize management of disease flare and/or irAEs in cancer patients, it will be helpful to
have larger prospective controlled studies to assess true comparative risks in this patient population, establish markers that are predictive for flares and/or irAEs, and determine the best methods of preventing and treating flares and irAEs while preserving cancer treatment efficacy.

Conclusion
Overall, we showed in our analysis of 45 patients with pre-existing autoimmune rheumatologic diseases treated with ICI therapy that over half of the patients experienced a flare or irAE but the majority of these were not life threatening. Continuation of anti-rheumatic therapy during ICI therapy did not prevent disease flares or new onset irAEs, nor did it impact cancer outcome. Further research is needed to determine if there are safe and effective anti-rheumatic therapy options to prevent and treat flares and irAEs in patients with rheumatologic disease on ICI therapy.

Abbreviations
CDW-H: Carolina data warehouse for health; CI: Confidence interval; CTCAE: Common terminology criteria for adverse events; CTLA-4: Cytotoxic T-lymphocyte associated protein 4; DMARD: Disease modifying anti-rheumatic drug; ECOG: Eastern cooperative oncology group; EMERSE: Electronic medical record search engine; I2B2: Informatics for integrating biology and the bedside; ICI: Immune checkpoint inhibitors; irAE: Immune-related adverse events; NSCLC: Non-small cell lung cancer; OR: Odds ratio; PD-1: Programmed cell death protein 1; PD-L1: Programmed death ligand 1; RA: Rheumatoid arthritis; RD: Risk difference; UNC: University of North Carolina.

Acknowledgements
Amanda Nelson MD: Review & Editing

Author contributions
SSB: Project administration, Writing - Review & Editing, CA: MS: Formal statistical analysis, Writing - Review & Editing, TS: Formal statistical analysis, Supervision, Writing - Review & Editing, AL: Conceptualization, Investigation, Writing - Original Draft. All authors read and approved the final manuscript.

Funding
This study was supported by the UNC Thurston Arthritis Research Center Dean’s Fund, TARC 2019 Pilot Research Grant, the NIH National Center for Advancing Translational Sciences (NCATS) (#UL1TR002489 and #UL1TR001111) and UNC CCCR Grant (NIH-NIGMS P30AR072580).

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study was reviewed and approved by the Institutional Review Board of the University of North Carolina at Chapel Hill prior to start of data collection under IRB 17-1841. All methods were performed in accordance with the relevant guidelines and regulations. Due to the retrospective design and observational nature of the study, the requirement for informed consent was waived by the ethics committee of the University of North Carolina at Chapel Hill.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, USA. 2Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, USA. 3Department of Biostatistics, Gillings School of Global Public Health and Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, USA.

Received: 3 March 2022 Accepted: 20 July 2022
Published online: 08 November 2022

References
1. Spiers L, Coupe N, Payne M. Toxicities associated with checkpoint inhibitors—an overview. Rheumatology (Oxford). 2019;58(7):vi7–16.
2. Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J. 2021;23(2):39.
3. Kostine M, Rouxel L, Barretche T, Veillon R, Martin F, Dutraux C, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2018;77(3):393–8.
4. Warner BL, Baer AN, Lipson EJ, Allen C, Hinrichs C, Ragan A, et al. Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncologist. 2019;24(9):1259–69.
5. Moreira A, Loquai C, Pföhler C, Kahler KC, Krauss S, Hepp MV, et al. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer. 2019;106:12–23.
6. Almutairi KB, Nossent JC, Preen DB, Keen HI, Inderjeeth CA. The prevalence of rheumatoid arthritis: a systematic review of population-based studies. J Rheumatol. 2021;48(5):669–76.
7. Gat E, Ehrenfeld M, Shoenfeld Y. Cancer and autoimmune diseases. Autoimmun Rev. 2017;16(10):1049–57.
8. Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2(2):234–40.
9. Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L, et al. Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol. 2018;36(19):1905–12.
10. Richter MD, Pinkston O, Kottscadle LA, Finnes HD, Markovic SN, Thana-rasingam U. Brief report: cancer immunotherapy in patients with preexisting rheumatic disease: the mayo clinic experience. Arthritis Rheumatol. 2018;70(3):356–60.
11. Tison A, Quere G, Misery L, Funk-Brentano E, Danlos FX, Routier E, et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide multicenter cohort study. Arthritis Rheumatol. 2019;71(12):2100–11.
12. Cortellini A, Bulli S, Santini D, Perrone F, Giusi R, Tiseo M, et al. Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study. Oncologist. 2019;24(6):e327–37.
13. Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 2018;81:21–9.
14. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28(2):368–76.
15. van der Kooij MK, Suikerbuij KPM, Aarts MJB, van den Berkmortel F, Blank CU, Boers-Sonderen MJ, et al. Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease: a cohort study. Ann Intern Med. 2021;171:641–8.
16. Lee B, Wong A, Kee D, Neeson P, Shackleton M, McArthur G, et al. The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma. Ann Oncol. 2016;27(8):1174–7.
17. Efuni E, Cytryn S, Boland P, Niewold TB, Pavlick A, Weber J, et al. Risk of toxicity after initiating immune checkpoint inhibitor treatment in patients with rheumatoid arthritis. J Clin Rheumatol. 2020;27:267–71.
18. Hanauer DA, Mei Q, Law J, Khanna R, Zheng K. Supporting information retrieval from electronic health records: a report of University of Michigan’s nine-year experience in developing and using the electronic medical record search engine (EMERSE). J Biomed Inf. 2015;55:290–300.
19. El Osta B, Hu F, Sadek R, Chintalapally R, Tang SC. Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol. 2017;119:1–12.
20. Nishimura H, Nose M, Hai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141–51.
21. Sandigursky S, Silverman GJ, Mor A. Targeting the programmed cell death-1 pathway in rheumatoid arthritis. Autoimmun Rev. 2017;16(8):767–73.
22. Raptopoulou AP, Bertsias G, Makrygiannakis D, Verginis P, Kritikos I, Tzardi M, et al. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum. 2010;62(7):1870–80.
23. Li J, He Q, Yu X, Khan K, Weng X, Guan M. Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials. Cancer Manag Res. 2019;11:1623–9.
24. Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol. 2018;36(17):1668–74.
25. Petrelli F, Signorelli D, Ghidini M, Ghidini A, Pizzutilo EG, Ruggieri L, et al. Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers (Basel). 2020;12(3):546.
26. Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM. Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications. J Clin Oncol. 2019;37(22):1927–34.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.